Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series

Main Article Content

Shahrzad Zonoozi


Thalassemic Syndromes, Diabetes


Sitagliptin, a modern antidiabetic agent which is weight neutral and associated with low rate of hypoglycaemias, is being increasingly used in type 2 diabetes mellitus (DM). However there is paucity of data about its efficacy and safety in beta-thalassaemia major (?-TM).

This retrospective case series of five patients (mean age of 45 years) is the first study evaluating the use of sitagliptin in patients with ?-TM and DM.

Four patients responded well to sitagliptin, as evidenced by decrease in fructosamine by 77 and 96µmol/L (equivalent reduction in HbA1c of 1.5% and 1.9%) observed in two patients and reduction in the frequency of hypoglycaemia without worsening glycaemic control in two others. One patient did not respond to sitagliptin. No patients reported significant side effects.

This study provides evidence that sitagliptin may be considered, with caution, for use in patients with ?-TM and DM, under the close monitoring of a Diabetologist.


Download data is not yet available.

Abstract 2358
PDF Downloads 733
HTML Downloads 1204


1. Barnard M, Tzoulis P. Diabetes and thalassaemia. Thalassemia Reports, 2013. 3(1s): p. 18.
2. Tzoulis P. Review of endocrine complications in adult patients with ?-thalassaemia major. Thalassemia Reports, 2014. 4(3).
3. De Sanctis V, Soliman AT, Elsedfy H, Pepe A, Kattamis C, El Kholy M, Yassin M. Diabetes and Glucose Metabolism in Thalassemia Major: An Update. Expert Review of Hematology, 2016. 9(4): p. 401-408.
4. Monge L, Pinach S, Caramellino L, Bertero MT, Dall'omo A, Carta Q. The possible role of autoimmunity in the pathogenesis of diabetes in B-thalassemia major. Diabetes Metab, 2001. 27(2 Pt 1): p. 149-54.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015. 38(1): p. 140-149.
6. Lee M, Rhee MK. Sitagliptin for Type 2 diabetes: a 2015 update. Expert Rev Cardiovasc Ther, 2015. 13(6): p. 597-610.
7. Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, Duan W, Zhou SF. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology, 2015. 42(10): p. 999-1024.
8. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism, 2007. 9(2): p. 194-205.
9. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract, 2010. 64(5): p. 562-76.
10. Cappellini M-D C. A., Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd Revised edition ed. 2008: Thalassaemia International Federation.
11. Juraschek SP, Steffes MW, Selvin E. Associations of Alternative Markers of Glycemia with Hemoglobin A1c and Fasting Glucose. Clinical Chemistry, 2012. 58(12): p. 1648-1655.
12. Ahuja V, Chou CH. Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness. Curr Diab Rep, 2016. 16(6): p. 47.
13. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA, 2007. 298(2): p. 194-206.
14. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2008(2): p. Cd006739.
15. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2012. 14(12): p. 1061-1072.
16. Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes, Obesity and Metabolism, 2016: p. n/a-n/a.
17. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf, 2015. 14(4): p. 505-24.
18. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med, 2014. 370(9): p. 794-7.
19. Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes/Metabolism Research and Reviews, 2016. 32(4): p. 391-404.
20. US Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015 [cited 2016; Available from: http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm]

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.